Vector Pharma FZCO entered into an exclusive distribution agreement with Danish company Ascendis Pharma to commercialize both Skytrofa and Yorvipath in the Gulf Cooperation Council countries of Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain. Under the terms of this exclusive distribution agreement, Vector will employ its sales and marketing expertise to distribute both Skytrofa and Yorvipath to patients in the GCC countries for the treatment of pediatric growth hormone deficiency in the case of Skytrofa, and adult hypoparathyroidism in the case of Yorvipath.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma Introduces Vision 2030
- Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
- Ascendis Pharma announces new analyses from OLE portions of ACcomplisH
- Ascendis Pharma price target raised to $202 from $200 at Wedbush
